Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...
Rahul Nambiampurath has been writing and reporting about cryptocurrency since 2017. As a fan of decentralized tech, he was fascinated by the Bitcoin whitepaper. Erika Rasure is globally-recognized as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results